Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Declares Outbreak Past Peak, But Drug Makers Far From Recovery

Good Old Days May Never Return?

Executive Summary

Clinical studies in hiatus, marketing on hold, demand directionless and supply disrupted. Pharma firms in China say it’s likely the good old days may never come back.

You may also be interested in...



Volume-Based Purchasing Looms Larger In Post-Coronavirus China

China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.

Coronavirus Update: Trump Spreads Confusion On Drug Treatments, Biogen Fires China Flight Employee

Daily round-up of the latest coronavirus news: Trump's chloroquine mix-up, imported cases rise in China, Biogen sacks employee over China travel, Vir's Scango talks about its COVID-19 efforts, Roche's Actemra study plus COVID-19 pipeline infographic.

3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China

A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel